BIO, Belgium's investor in SMEs and funds in developing countries

The mandate, and what indirectly means

BIO invests directly and indirectly in SMEs in emerging and developing countries. Indirectly means through funds and holding companies, which is stated in the strategy as one of its two structural routes rather than as an occasional exception.

The sectors the strategy names span banks, microfinance and fintech, insurance, enterprises, agriculture and other value chains, renewable energy, and telecoms. Read across those, BIO is a financial-sector investor first and a direct SME investor second, which its own numbers bear out.

What the strategy commits to, in its own numbers

The 2024 to 2028 strategy sets targeted average approvals by sector. Financial institution loans are targeted at 29 percent of approvals, financial institution equity at 10 percent, infrastructure loans at 18 percent, private equity funds at 37 percent, and direct SMEs at 7 percent. Private equity funds are therefore the largest single approval target in the plan.

It also sets an instrument split, targeting 35 percent of the portfolio in equity, meaning private equity funds and direct equity, against 40 percent in loans.

The strategy is unusually candid about returns. It states that the financial sector in debt and equity, and to a lesser extent debt funds, have provided consistent positive net return, that private equity funds and infrastructure projects are about break-even, and that investments in direct SMEs have clearly run a loss. A manager pitching a private equity fund should know that BIO's own analysis places that product at break-even and has still raised its approval target.

The limits are concentration percentages, not ticket sizes

The strategy publishes concentration limits as net approved commitment expressed as a percentage of total assets, under two mandate codes. For BIO Capital the limits are 10 percent per country, 5 percent per client, 60 percent per continent, and 5 percent per off-taker. For Capital Subsidies they are 20 percent per country and 12 percent per client, with no continent limit.

Those are portfolio risk limits on BIO's own balance sheet. They are not an investment range, and they do not tell a manager what BIO would commit to a fund.

No standard fund ticket is publicly stated. BIO does not publish an expected commitment size for its fund route on the sources cited here, and this page does not construct one from a portfolio target or a concentration limit.

How this may fit

The general development finance readiness layer applies, and the DFI pathway guide covers it. What is specific to BIO is where its capital is actually pointed.

• Position a fund against the private equity funds line, which carries the largest approval target in BIO's plan.
• Expect scrutiny on returns, given that BIO's own strategy calls private equity funds about break-even for it historically.
• Consider whether a financial-institution strategy fits better, since financial sector debt and equity together carry the largest share of BIO's approvals and its best stated returns.
• Ask about sizing directly, because nothing is published, and do not read a concentration limit as an available amount.
• Check the EDFI exclusion list early, which BIO applies alongside the other European bilaterals in this directory.